Compare ABEO & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | RLTY |
|---|---|---|
| Founded | 1974 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 247.3M |
| IPO Year | 1980 | N/A |
| Metric | ABEO | RLTY |
|---|---|---|
| Price | $5.52 | $14.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.20 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 86.7K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.35% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,590.36 | N/A |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $11.38 |
| 52 Week High | $7.54 | $14.60 |
| Indicator | ABEO | RLTY |
|---|---|---|
| Relative Strength Index (RSI) | 61.06 | 30.76 |
| Support Level | $4.80 | $14.52 |
| Resistance Level | $5.61 | $14.69 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 91.63 | 14.46 |
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.